Posted by Michael Wonder on 30 Jan 2023
Alpha Biopharma submits new drug application for zorifertinib, a next generation EGFR-TKI to treat EGFR mutated NSCLC patients with CNS metastases
30 January 2023 - Alpha Biopharma announces that the Center for Drug Evaluation of the NMPA has accepted its new drug application for zorifertinib, a next generation EGFR-TKI specially designed to treat advanced EGFR mutated non-small cell lung cancer patients with central nervous system metastases.
Zorifertinib is the first EGFR-TKI to be tested in a prospective, controlled registration clinical study for this difficult to treat patient population, and if approved, it will bring a much needed new treatment option for these patients.
